Skip to main content
ALMS
NASDAQ Life Sciences

Alumis Inc. Raises $345.1M in Public Offering, Significant Dilution Expected

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$18.39
Mkt Cap
$1.898B
52W Low
$2.76
52W High
$22.3
52W Position info
566% above low
Off High info
18% below high
Rel. Volume info
4.3× avg
Market data snapshot near publication time

ALMS has more than doubled off its 52-week low of $2.76 on elevated volume (4.3× avg).

Summary

Alumis Inc. announced a public offering of 20.3 million shares at $17.00 per share, raising approximately $345.1 million, which represents substantial dilution for existing shareholders.


Key Events · Financing and Capital Events · ALMS

  • Public Offering Announced

    Alumis Inc. entered into an underwriting agreement for a public offering of 17,650,000 shares of common stock.

  • Underwriters' Option Exercised

    The underwriters fully exercised their option to purchase an additional 2,647,500 shares, bringing the total offering to 20,297,500 shares.

  • Gross Proceeds

    The offering is expected to generate gross proceeds of approximately $345.1 million for the company.

  • Offering Price

    Shares were priced at $17.00 per share, a discount to the current market price of $18.39.


Analysis · ALMS · Life Sciences

Alumis Inc. announced a substantial public offering of 20,297,500 shares of common stock, including the full exercise of the underwriters' option, at a price of $17.00 per share. This offering is expected to generate gross proceeds of approximately $345.1 million for the company. While securing significant capital to extend its financial runway, the offering represents considerable dilution for existing shareholders. The offering price of $17.00 per share is at a discount compared to the current market price of $18.39. This capital raise follows the company's preliminary unaudited cash, cash equivalents, and marketable securities balance of approximately $308.6 million as of December 31, 2025.

How filings like this one have moved

In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALMS was trading at $18.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $2.76 to $22.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALMS - Latest Insights

ALMS
Sep 09, 2026, 9:39 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $9.82
Real-time Price: $9.25 info
Change: -$0.570 (-6%) info
Market Cap: $1.225B info
ALMS
Sep 01, 2026, 10:56 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.04
Real-time Price: $9.25 info
Change: +$0.2099 (+2%) info
Market Cap: $1.225B info
ALMS
Sep 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $9.25 info
Change: -$13.55 (-59%) info
Market Cap: $1.225B info
ALMS
Sep 01, 2026, 7:34 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $22.80
Real-time Price: $9.25 info
Change: -$13.55 (-59%) info
Market Cap: $1.225B info
ALMS
Aug 17, 2026, 6:09 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $25.30
Real-time Price: $9.25 info
Change: -$16.05 (-63%) info
Market Cap: $1.225B info